Covaxin booster

Covaxin booster successful in neutralizing Omicron variant- Bharat Biotech

Health Health

Covaxin (BBV152) booster dosage has been demonstrated to neutralize both Omicron and Delta variants of COVID-19, according to Bharat Biotech. According to the institution, a booster dosage of Covaxin resulted in strong neutralization of the Delta version, and more than 90% of blood samples exhibited neutralization of the Omicron variation.

The Omicron variant, which was initially discovered in late November of last year in South Africa, has sparked a new wave of infections throughout the globe.

The research was carried out by Ocugen, an Indian vaccine maker’s partner, at the Emory Vaccine Centre in Atlanta (US), as part of ongoing phase 2 clinical trials in which immunological sera from 13 trial participants were tested 28 days following their booster shots.

The booster doses were given six months after the individuals had their entire immunization with two initial doses.

Cell-mediated immunity and neutralizing antibodies against both homologous (D614G) and heterologous (Alpha, Beta, Delta, and Delta plus) strain sustained above baseline six months following a two-dose Covaxin (BBV152) vaccination series, the firm stated, however, the amplitude of the responses had reduced.

According to Krishna Ella, CMD of the good neutralizing responses against the Omicron and Delta variants corroborate their concept of a multi-epitope vaccination causing both humoral and cell-mediated immune responses in Hyderabad-based companies.

The results of the ongoing study are set to be published in a medical research pre-print repository.